zinc finger and SCAN domain containing 22Genealiases: HKR2 · ZNF50
Q-omics provides the consensus-scored ZSCAN22 profile across patient tissues and cancer cell-line models. ZSCAN22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZSCAN22 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ZSCAN22 RNA expression shows 20,067 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, BLCA, and ACC as cancer lineages where ZSCAN22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN22 survival associations across molecular data types. ZSCAN22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN22 RNA expression–survival associations across cancer types. High ZSCAN22 expression shows unfavorable associations in MESO, ACC, KIRP and LGG, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZSCAN22 RNA expression.
This table summarizes ZSCAN22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZSCAN22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN22 shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, HNSC, KIRC and READ. The BLCA box plot shows higher ZSCAN22 RNA expression in tumor versus normal tissue (log2 FC = +0.496, t-test p < 0.001).
This table shows molecular features associated with ZSCAN22 in patient tissues and cancer cell lines. In patient samples, ZSCAN22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
